Evoke Pharma Price to Free Cash Flow Ratio 2012-2023 | EVOK
Historical price to free cash flow ratio values for Evoke Pharma (EVOK) since 2012.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Evoke Pharma Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-26 |
0.46 |
|
0.00 |
| 2023-12-31 |
1.05 |
$-2.37 |
0.00 |
| 2023-06-30 |
1.65 |
$-2.00 |
0.00 |
| 2023-03-31 |
1.90 |
$-1.99 |
0.00 |
| 2022-12-31 |
2.68 |
$-2.10 |
0.00 |
| 2022-09-30 |
1.87 |
$-4.67 |
0.00 |
| 2022-06-30 |
3.24 |
$-1.73 |
0.00 |
| 2022-03-31 |
5.94 |
$-3.54 |
0.00 |
| 2021-12-31 |
6.60 |
$-3.47 |
0.00 |
| 2023-09-30 |
1.38 |
$-1.16 |
0.00 |
| 2021-09-30 |
15.60 |
$-4.68 |
0.00 |
| 2021-06-30 |
16.44 |
$-3.28 |
0.00 |
| 2021-03-31 |
21.96 |
$-3.50 |
0.00 |
| 2020-12-31 |
30.96 |
$-3.12 |
0.00 |
| 2020-09-30 |
56.28 |
$-3.06 |
0.00 |
| 2020-06-30 |
42.48 |
$-2.76 |
0.00 |
| 2020-03-31 |
13.92 |
$-2.54 |
0.00 |
| 2019-12-31 |
19.44 |
$-3.10 |
0.00 |
| 2019-09-30 |
10.32 |
$-3.33 |
0.00 |
| 2019-06-30 |
7.50 |
$-3.53 |
0.00 |
| 2019-03-31 |
18.00 |
$-4.18 |
0.00 |
| 2018-12-31 |
29.76 |
$-5.05 |
0.00 |
| 2018-09-30 |
35.76 |
$-6.34 |
0.00 |
| 2018-06-30 |
30.00 |
$-7.40 |
0.00 |
| 2018-03-31 |
24.96 |
$-7.70 |
0.00 |
| 2017-12-31 |
27.12 |
$-7.00 |
0.00 |
| 2017-09-30 |
40.08 |
$-7.57 |
0.00 |
| 2017-06-30 |
30.70 |
$-5.96 |
0.00 |
| 2017-03-31 |
37.20 |
$-8.19 |
0.00 |
| 2016-12-31 |
24.24 |
$-11.19 |
0.00 |
| 2016-09-30 |
27.12 |
$-12.86 |
0.00 |
| 2016-06-30 |
82.20 |
$-16.91 |
0.00 |
| 2016-03-31 |
61.08 |
$-18.04 |
0.00 |
| 2015-12-31 |
39.60 |
$-19.43 |
0.00 |
| 2015-09-30 |
34.92 |
$-19.94 |
0.00 |
| 2015-06-30 |
62.76 |
$-23.50 |
0.00 |
| 2015-03-31 |
84.60 |
$-24.78 |
0.00 |
| 2014-12-31 |
70.80 |
$-22.89 |
0.00 |
| 2014-09-30 |
65.99 |
$-21.61 |
0.00 |
| 2014-06-30 |
97.08 |
$-25.51 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
